GlobeNewswire: SQZ Biotech Contains the last 10 of 17 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:32:45ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/01/30/1977468/0/en/SQZ-Biotech-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-SQZ-PBMC-HPV-for-HPV-Tumors.html?f=22&fvtc=4&fvtv=51456SQZ Biotech Announces First Patient Dosed in Phase 1 Trial of SQZ-PBMC-HPV for HPV+ Tumors2020-01-30T13:00:00Z<![CDATA[Trial is evaluating SQZ-PBMC-HPV as both monotherapy and in combination with a checkpoint inhibitor]]>https://www.globenewswire.com/news-release/2019/11/12/1945282/0/en/SQZ-Biotech-to-Present-at-Upcoming-Investor-Conferences-in-November-December.html?f=22&fvtc=4&fvtv=51456SQZ Biotech to Present at Upcoming Investor Conferences in November & December2019-11-12T13:00:00Z<![CDATA[WATERTOWN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will present a corporate overview at the Stifel 2019 Healthcare Conference in New York City, the Jefferies 2019 London Healthcare Conference in London, United Kingdom, and the Evercore ISI HEALTHCONx Conference in Boston.]]>https://www.globenewswire.com/news-release/2019/11/07/1943093/0/en/SQZ-Biotech-and-AskBio-Announce-Research-Collaboration-to-Create-Immune-Tolerization-Products-for-AAV-Gene-Therapies.html?f=22&fvtc=4&fvtv=51456SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies 2019-11-07T13:00:00Z<![CDATA[Scientific leaders in cell and gene therapy collaborate to determine efficacy of SQZ tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses to AAV Scientific leaders in cell and gene therapy collaborate to determine efficacy of SQZ tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses to AAV]]>https://www.globenewswire.com/news-release/2019/11/05/1941145/0/en/SQZ-Biotech-to-Present-First-Time-Data-Demonstrating-Potential-of-Company-s-Second-Novel-Cell-Therapy-Approach-in-Oncology-Activating-Antigen-Carriers-AACs.html?f=22&fvtc=4&fvtv=51456SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology - Activating Antigen Carriers (AACs)2019-11-05T13:01:00Z<![CDATA[Preclinical data demonstrate SQZ AACs ability to prime antigen-specific T cell responses and drive tumor reduction in vivo]]>https://www.globenewswire.com/news-release/2019/10/31/1938674/0/en/SQZ-Biotech-to-Present-New-Data-at-the-Society-for-Immunotherapy-of-Cancer-s-34th-Annual-Meeting.html?f=22&fvtc=4&fvtv=51456SQZ Biotech to Present New Data at the Society for Immunotherapy of Cancer’s 34th Annual Meeting2019-10-31T12:00:00Z<![CDATA[WATERTOWN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will present two abstracts on cellular therapies at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting on November 6-10, 2019 in National Harbor, Maryland.]]>https://www.globenewswire.com/news-release/2019/10/22/1933137/0/en/SQZ-Biotech-Announces-Clearance-of-US-IND-Application-for-First-Clinical-Trial.html?f=22&fvtc=4&fvtv=51456SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial2019-10-22T12:00:00Z<![CDATA[First program advancing into the clinic through the SQZ-Roche collaboration in APCs for oncology First program advancing into the clinic through the SQZ-Roche collaboration in APCs for oncology]]>https://www.globenewswire.com/news-release/2019/09/17/1916586/0/en/SQZ-Biotech-Appoints-Legal-Life-Sciences-Expert-Lawrence-Knopf-as-General-Counsel.html?f=22&fvtc=4&fvtv=51456SQZ Biotech Appoints Legal Life Sciences Expert, Lawrence Knopf, as General Counsel2019-09-17T12:00:00Z<![CDATA[WATERTOWN, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appointment of Lawrence Knopf as the company’s general counsel. Mr. Knopf joins SQZ with a unique perspective on the life sciences industry and an excellent combination of corporate, intellectual property and business expertise.]]>https://www.globenewswire.com/news-release/2019/08/07/1898764/0/en/SQZ-Biotech-Announces-Appointment-of-Experienced-Pharmaceutical-Executive-Teri-Loxam-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=51456SQZ Biotech Announces Appointment of Experienced Pharmaceutical Executive Teri Loxam as Chief Financial Officer2019-08-07T20:30:00Z<![CDATA[WATERTOWN, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appointment of Teri Loxam as chief financial officer. Ms. Loxam joins SQZ with deep experience in investor relations, strategy, corporate communications and finance. She most recently served as senior vice president of investor relations and global communications at Merck & Co. At SQZ, Ms. Loxam will be responsible for leading the company’s financial and investor activities.]]>https://www.globenewswire.com/news-release/2019/05/29/1856270/0/en/SQZ-Biotech-Strengthens-Board-of-Directors-with-Appointment-of-Leading-Cell-Therapy-Expert-and-Biotech-Veteran.html?f=22&fvtc=4&fvtv=51456SQZ Biotech Strengthens Board of Directors with Appointment of Leading Cell Therapy Expert and Biotech Veteran2019-05-29T12:00:00Z<![CDATA[Isaac Ciechanover, MD, MBA, to join board of directors as SQZ prepares to enter the clinic with its initial oncology program Isaac Ciechanover, MD, MBA, to join board of directors as SQZ prepares to enter the clinic with its initial oncology program]]>https://www.globenewswire.com/news-release/2019/05/14/1823655/0/en/SQZ-Biotech-to-Present-at-Investor-Conferences-in-May-June.html?f=22&fvtc=4&fvtv=51456SQZ Biotech to Present at Investor Conferences in May & June2019-05-14T12:00:00Z<![CDATA[WATERTOWN, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will present a corporate overview at the UBS Global Healthcare Conference and the Jefferies 2019 Healthcare Conference in New York City.]]>